Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 44 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ESTETRA from Liège, company number BE0818257356, closed financial year 2025 with a result of € -18.1 million after tax. For that financial year ESTETRA recorded revenue of € 21 million and equity of € -2 million. Compared with financial year 2024, the result moved from € -76.3 million to € -18.1 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.
€ -2 million
▲ € 21.5 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -18.1 million
▲ 76 % less loss than in 2024
Profit after tax over the fiscal year.
€ 10.2 million
▲ 39% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -96.1 million.
People and assets in 2025
40.3
▼ 3.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 6.4 million
▼ 3% vs 2024
€ 159,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 80,529
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 721,030
▼ 6% vs 2024
Loans from banks and other lenders, long and short.
€ 14.3 million
▲ 71% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 146 days on average.
€ 1.6 million
▲ 11% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 16,374,250 | € 66,875,099 | € 31,470,124 | € 21,036,596 | ▼ 33% |
| Profit after taxes | € -76,363,141 | € -1,658,449 | € -76,324,666 | € -18,124,817 | ▲ € 58.2 million |
| Equity | € 31,248,444 | € 29,198,191 | € -23,528,370 | € -2,044,990 | ▲ € 21.5 million |
| Total debts | € 78,612,045 | € 52,594,277 | € 100,309,583 | € 68,662,883 | ▼ 32% |
| Cash | € 59,287 | € 3,127,073 | € 7,292,762 | € 10,167,030 | ▲ 39% |
| Retained profit | € -75,314,255 | € -609,563 | € -76,934,230 | € -96,107,932 | ▼ € 19.2 million |
| Bank debt | € 15,000,000 | € 14,250,000 | € 764,942 | € 721,030 | ▼ 6% |
| Balance sheet total | € 109,860,489 | € 81,792,468 | € 76,781,213 | € 66,617,893 | ▼ 13% |
| Employees (FTE) | 30.4 | 34.5 | 43.6 | 40.3 | ▼ 3.3 |
Key figures of ESTETRA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ESTETRA?
What happened at ESTETRA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Gábor Szücs stepped down as director. NBB
- Istvan Greiner stepped down as director. NBB
- Graham Keith Dixon stepped down as director. NBB
- Peter Turek stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 18.1 million. Source: NBB ↗
- Gábor Szücs became a director. NBB
- Graham Keith Dixon became a director. NBB
- Istvan Greiner became a director. NBB
In short
From € 76.4 million loss in 2022 to € 18.1 million loss in 2025.
Pays suppliers within 146 days on average.
A new publication or filing at ESTETRA? We notify you, reason included.
Follow ESTETRADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Chemical Works of Gedeon Richter Plc (100%).
Directors
According to the 2025 annual accounts
Gábor Szücs
Director
since 2025 · until 2030
Istvan Greiner
Director
since 2024 · until 2030
since 2025 · until 2030
since 2024 · until 2030
Shareholders
Chemical Works of Gedeon Richter Plc
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Saint-Georges 5
4000 Liège
Rue Saint-Georges 5-7
4000 Liège
Active since 9 May 2012
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0818.257.356
- VAT number
- BE 0818.257.356
- Registered office
- Rue Saint-Georges 5, 4000 Liège
- Names & denominations
- ESTETRA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 September 2009
- Peppol
- Active · Active since 3 Dec 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van overige farmaceutische producten
Activiteiten van medische beeldvorming en medische laboratoria
Vervaardiging van farmaceutische grondstoffen
Activiteiten van medische laboratoria